Pfizer (PFE) : J.p. Marvel Investment Advisors reduced its stake in Pfizer by 0.16% during the most recent quarter end. The investment management company now holds a total of 277,397 shares of Pfizer which is valued at $9,703,347 after selling 444 shares in Pfizer , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Pfizer makes up approximately 3.25% of J.p. Marvel Investment Advisors’s portfolio.
Other Hedge Funds, Including , Pioneer Investment Management Inc boosted its stake in PFE in the latest quarter, The investment management firm added 4,818,301 additional shares and now holds a total of 15,488,287 shares of Pfizer which is valued at $541,780,279. Pfizer makes up approx 1.92% of Pioneer Investment Management Inc’s portfolio.Bingham Osborn Scarborough boosted its stake in PFE in the latest quarter, The investment management firm added 584 additional shares and now holds a total of 14,737 shares of Pfizer which is valued at $522,279. Pfizer makes up approx 0.06% of Bingham Osborn Scarborough’s portfolio.Concorde Asset Management boosted its stake in PFE in the latest quarter, The investment management firm added 4,493 additional shares and now holds a total of 14,228 shares of Pfizer which is valued at $522,737. Pfizer makes up approx 0.51% of Concorde Asset Management’s portfolio.Tnb Financial boosted its stake in PFE in the latest quarter, The investment management firm added 18,265 additional shares and now holds a total of 49,193 shares of Pfizer which is valued at $1,804,399. Pfizer makes up approx 0.46% of Tnb Financial’s portfolio.
Pfizer closed down -0.12 points or -0.34% at $34.68 with 1,59,21,155 shares getting traded on Thursday. Post opening the session at $34.73, the shares hit an intraday low of $34.61 and an intraday high of $34.94 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.
Many Wall Street Analysts have commented on Pfizer. Shares were Reiterated by Jefferies on Jun 20, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.